Universität zu Köln

Mueller, Lukas, Hahn, Felix, Auer, Timo Alexander ORCID: 0000-0002-5763-689X, Fehrenbach, Uli ORCID: 0000-0003-3622-3268, Gebauer, Bernhard ORCID: 0000-0002-9948-7220, Haubold, Johannes, Zensen, Sebastian, Kim, Moon-Sung, Eisenblaetter, Michel, Diallo, Thierno D., Bettinger, Dominik, Steinle, Verena, Chang, De-Hua, Zopfs, David, Pinto dos Santos, Daniel and Kloeckner, Roman (2022). Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. Front. Oncol., 12. LAUSANNE: FRONTIERS MEDIA SA. ISSN 2234-943X

Full text not available from this repository.

Abstract

ObjectivesRecently, several scoring systems for prognosis prediction based on tumor burden have been promoted for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). This multicenter study aimed to perform the first head-to-head comparison of three scoring systems. MethodsWe retrospectively enrolled 849 treatment-naive patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. The tumor burden score (TBS), the Six-and-Twelve score (SAT), and the Seven-Eleven criteria (SEC) were calculated based on the maximum lesion size and the number of tumor nodes. All scores were compared in univariate and multivariate regression analyses, adjusted for established risk factors. ResultsThe median overall survival (OS) times were 33.0, 18.3, and 12.8 months for patients with low, medium, and high TBS, respectively (p<0.001). The median OS times were 30.0, 16.9, and 10.2 months for patients with low, medium, and high SAT, respectively (p<0.001). The median OS times were 27.0, 16.7, and 10.5 for patients with low, medium, and high SEC, respectively (p<0.001). In a multivariate analysis, only the SAT remained an independent prognostic factor. The C-Indexes were 0.54 for the TBS, 0.59 for the SAT, and 0.58 for the SEC. ConclusionIn a direct head-to-head comparison, the SAT was superior to the TBS and SEC in survival stratification and predictive ability. Therefore, the SAT can be considered when estimating the tumor burden. However, all three scores showed only moderate predictive power. Therefore, tumor burden should only be one component among many in treatment decision making.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mueller, Lukas UNSPECIFIED UNSPECIFIED UNSPECIFIED Hahn, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED Auer, Timo Alexander UNSPECIFIED orcid.org/0000-0002-5763-689X UNSPECIFIED Fehrenbach, Uli UNSPECIFIED orcid.org/0000-0003-3622-3268 UNSPECIFIED Gebauer, Bernhard UNSPECIFIED orcid.org/0000-0002-9948-7220 UNSPECIFIED Haubold, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Zensen, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kim, Moon-Sung UNSPECIFIED UNSPECIFIED UNSPECIFIED Eisenblaetter, Michel UNSPECIFIED UNSPECIFIED UNSPECIFIED Diallo, Thierno D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bettinger, Dominik UNSPECIFIED UNSPECIFIED UNSPECIFIED Steinle, Verena UNSPECIFIED UNSPECIFIED UNSPECIFIED Chang, De-Hua UNSPECIFIED UNSPECIFIED UNSPECIFIED Zopfs, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Pinto dos Santos, Daniel UNSPECIFIED UNSPECIFIED UNSPECIFIED Kloeckner, Roman UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-688742
DOI:	10.3389/fonc.2022.850454
Journal or Publication Title:	Front. Oncol.
Volume:	12
Date:	2022
Publisher:	FRONTIERS MEDIA SA
Place of Publication:	LAUSANNE
ISSN:	2234-943X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SUBCLASSIFICATION; PROGNOSIS Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68874